HIV Cure: Gene Therapy on CCR5 Receptor Showed Positive Result; One Patient Reached Undetectable Viral Levels
By Ryan Inoyori | March 10, 2014 5:41 PM EST
Scientists are now studying the possibility of replicating a genetic mutation on human T-cells to help fight HIV infection. It replicates the known genetic factor called CCR5 delta 32 that prevents HIV to attach itself with immune cells and render it unable to replicate in the body.
Engineering Immune Cells
Sangamo Biosciences conducted an experimental gene modifying strategy to control HIV effectively without ever needing any antiretroviral drugs or ART. In a small study performed on humans, researchers reported the engineering of a rare genetic mutation that is found to only 1 per cent of the world's population which protects carriers from becoming infected by the virus.
Some patients in their study received genetic modification treatment to resist HIV. They reported that some patients showed positive results by having decreased viral load during a temporary halt of antiretroviral drug treatment with surprising patient who reached undetectable viral levels in his blood.
"Sangamo's HIV suppression is promising but very early and far from a cure. This is very early study for technology and safety validation," Michael Yee analyst at RBC Capital Markets said according to Reuters.
Replicating CCR5 Delta 32
Sangamo Biosciences used a technique which disrupts a gene factor found in immune cells called CCR5 that is being used by HIV to attach itself, infect and replicate on T-cells. Altering CCR5 receptor will help disable the virus' ability to use T-cells to infect humans.
Each participant had their immune cells harvested from the blood, then researchers applied zinc-finger nucleases to edit genomes. Zinc finger nuclease breaks the copies of CCR5 gene, then infused back to the patient. However, performing such engineering isn't perfect as they cannot get every immune cell disrupted.
"About 25 per cent of the cells have at least one of the CCR5 genes interrupted," according to the CEO of Sangamo Biosciences, Edward Lanphier.
Rejection isn't a problem with this procedure since all cells came from the patient's but modified to resist HIV compared to regular immune cells.
Study notes include:
1. One week after infusion resulted in detectable modified T-cells in patients' blood.
2. Four weeks after infusion, six out of 12 patients had their ART stopped.
3. Four among six of those patients showed HIV levels dropped.
4. One patient's viral load reached undetectable levels in the blood.
5. Best responder is someone who had naturally mutated copy of CCR5 delta.
Individuals carrying disrupted CCR5 gene in their immune cells have slower progression to AIDS compared to infected patients with the undisrupted CCR5 gene. These immune cells with disrupted CCR5 gene becomes resistant against HIV and enables them to fight back infection.
To contact the editor, e-mail:
Join the Conversation
- Zero-Gravity Update: Coffee Machine Brews Fresh ISSpresso For Astronauts
- Stephen Hawking's Facebook Posts Tell You How The Cosmologist Reacts To 'Theory Of Everything' And 'Interstellar'
- Sydney Heatwave Roundup: Mercury Rising To 40 Degrees, Severe Fire Warnings In Place
- Crop Production Amplifies Carbon Dioxide Cycle
- Musical Training Enhances Long-Term Memory
- Black Friday 2014 Sale: Top Deals On Game Consoles Xbox One, PS4, Nintendo Wii U And More
- Walmart Pre-Black Friday 2014 Sale On Nov. 21, 2014 Includes Discounts On The 'NBA 2K15' For PS4 And The 'Skylanders Trap Team’ Starter Kit [WATCH VIDEO]
- Alleged 'Microsoft Lumia 1030' Front Panel Leaked With Capacitive Buttons; 'Xbox One' Owners To Get Free Goodies On Anniversary
- More Bad News for Android 5.0 Lollipop As Problems Come In for Nexus and Other Devices
- Black Friday 2014 Sale: Top 9 TV Deals Starting From $99 To $899
- BlackBerry Classic (aka Q20) Keyboard Shortcuts Explained In A Quick Video
- Julie Bishop Condemns Barack Obama For Overlooking Australia’s Commitment in Protecting Great Barrier Reef